000140184 001__ 140184
000140184 005__ 20240321220748.0
000140184 0247_ $$2doi$$a10.1016/j.jns.2018.03.033
000140184 0247_ $$2pmid$$apmid:29801904
000140184 0247_ $$2ISSN$$a0022-510X
000140184 0247_ $$2ISSN$$a1878-5883
000140184 0247_ $$2altmetric$$aaltmetric:35005597
000140184 037__ $$aDZNE-2020-06506
000140184 041__ $$aEnglish
000140184 082__ $$a610
000140184 1001_ $$0P:(DE-HGF)0$$aLessard, Isabelle$$b0
000140184 245__ $$aAssessing mobility and balance in Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay population: Validity and reliability of four outcome measures.
000140184 260__ $$aAmsterdam [u.a.]$$bElsevier Science$$c2018
000140184 264_1 $$2Crossref$$3print$$bElsevier BV$$c2018-07-01
000140184 3367_ $$2DRIVER$$aarticle
000140184 3367_ $$2DataCite$$aOutput Types/Journal article
000140184 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1706088591_14280
000140184 3367_ $$2BibTeX$$aARTICLE
000140184 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140184 3367_ $$00$$2EndNote$$aJournal Article
000140184 520__ $$aTo assess the construct validity of the 10-Meter Walk Test (10mWT), Six-Minute Walk Test (6MWT), Berg Balance Scale (BERG), and Timed Up and Go (TUG) in adults with Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay (ARSACS), in addition to the interrater reliability of the 10mWT and 6MWT.Reliability was determined using the intraclass correlation coefficient (ICC). Validity was determined first by correlating the 10mWT, 6MWT, BERG, and TUG with participant's age, lower limb coordination, and disease severity, and then by assessing their capacity to distinguish between participants based on sex and disease stages.Interrater reliability of the 10mWT at both comfortable and maximum speed as well as the 6MWT is excellent (ICC = 0.97-0.99). Construct validity of the four tests was confirmed, as showed by the high correlations with age, lower limb coordination, and overall disease severity (ρ = 0.64-0.97).The four tests assessed for their metrological properties in this study showed to be valid instruments to use in the ARSACS population. The 10mWT and 6MWT are also highly reliable. BERG and TUG reliability will need to be assess in a future study.
000140184 536__ $$0G:(DE-HGF)POF3-345$$a345 - Population Studies and Genetics (POF3-345)$$cPOF3-345$$fPOF III$$x0
000140184 542__ $$2Crossref$$i2018-07-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000140184 588__ $$aDataset connected to CrossRef, PubMed,
000140184 650_2 $$2MeSH$$aAdolescent
000140184 650_2 $$2MeSH$$aAdult
000140184 650_2 $$2MeSH$$aBiomechanical Phenomena
000140184 650_2 $$2MeSH$$aDisease Progression
000140184 650_2 $$2MeSH$$aFemale
000140184 650_2 $$2MeSH$$aHumans
000140184 650_2 $$2MeSH$$aMale
000140184 650_2 $$2MeSH$$aMiddle Aged
000140184 650_2 $$2MeSH$$aMovement
000140184 650_2 $$2MeSH$$aMuscle Spasticity: diagnosis
000140184 650_2 $$2MeSH$$aMuscle Spasticity: physiopathology
000140184 650_2 $$2MeSH$$aMuscle Spasticity: rehabilitation
000140184 650_2 $$2MeSH$$aPostural Balance
000140184 650_2 $$2MeSH$$aReproducibility of Results
000140184 650_2 $$2MeSH$$aSeverity of Illness Index
000140184 650_2 $$2MeSH$$aSex Characteristics
000140184 650_2 $$2MeSH$$aSpinocerebellar Ataxias: congenital
000140184 650_2 $$2MeSH$$aSpinocerebellar Ataxias: diagnosis
000140184 650_2 $$2MeSH$$aSpinocerebellar Ataxias: physiopathology
000140184 650_2 $$2MeSH$$aSpinocerebellar Ataxias: rehabilitation
000140184 650_2 $$2MeSH$$aWalk Test: methods
000140184 650_2 $$2MeSH$$aWheelchairs
000140184 650_2 $$2MeSH$$aYoung Adult
000140184 7001_ $$0P:(DE-HGF)0$$aBrais, Bernard$$b1
000140184 7001_ $$0P:(DE-HGF)0$$aCôté, Isabelle$$b2
000140184 7001_ $$0P:(DE-HGF)0$$aLavoie, Caroline$$b3
000140184 7001_ $$0P:(DE-2719)2811275$$aSynofzik, Matthis$$b4$$udzne
000140184 7001_ $$0P:(DE-HGF)0$$aMathieu, Jean$$b5
000140184 7001_ $$0P:(DE-HGF)0$$aGagnon, Cynthia$$b6$$eCorresponding author
000140184 77318 $$2Crossref$$3journal-article$$a10.1016/j.jns.2018.03.033$$b : Elsevier BV, 2018-07-01$$p4-9$$tJournal of the Neurological Sciences$$v390$$x0022-510X$$y2018
000140184 773__ $$0PERI:(DE-600)1500645-1$$a10.1016/j.jns.2018.03.033$$gVol. 390, p. 4 - 9$$p4-9$$q390<4 - 9$$tJournal of the neurological sciences$$v390$$x0022-510X$$y2018
000140184 8564_ $$uhttps://pub.dzne.de/record/140184/files/DZNE-2020-06506_Restricted.pdf
000140184 8564_ $$uhttps://pub.dzne.de/record/140184/files/DZNE-2020-06506_Restricted.pdf?subformat=pdfa$$xpdfa
000140184 909CO $$ooai:pub.dzne.de:140184$$pVDB
000140184 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811275$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000140184 9131_ $$0G:(DE-HGF)POF3-345$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vPopulation Studies and Genetics$$x0
000140184 9141_ $$y2018
000140184 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2022-11-08$$wger
000140184 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ NEUROL SCI : 2021$$d2022-11-08
000140184 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2022-11-08
000140184 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2022-11-08
000140184 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2022-11-08
000140184 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2022-11-08
000140184 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2022-11-08
000140184 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2022-11-08
000140184 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2022-11-08
000140184 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2022-11-08
000140184 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2022-11-08
000140184 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x0
000140184 980__ $$ajournal
000140184 980__ $$aVDB
000140184 980__ $$aI:(DE-2719)1210000
000140184 980__ $$aUNRESTRICTED